Nektar Therapeutics
IPO
Pioneering science to transform patient lives through innovative immunology therapies
- Headquarters
- San Francisco, California
- Employees
- 51–200
- Founded
- 1990
- Business Model
- B2B
- Website
- nektar.com
- Total Funding
- $460.0M
- Last Round
- $460.0M Corporate RoundFeb 2026
About
Nektar Therapeutics is a clinical-stage biopharmaceutical company headquartered in San Francisco, California. Founded in 1990, Nektar has led development in PEGylation technology — attaching polyethylene glycol (PEG) polymer chains to drug molecules to improve their pharmacokinetics. The company subsequently pivoted to immunology, developing novel small-molecule and biologic therapies for conditions including atopic dermatitis and multiple sclerosis. Its lead asset NKTR-0165 demonstrated strong Phase 2b results in eczema in early 2026. Nektar went public in 1994 (Nasdaq: NKTR).
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account